Pharma BD Deal Intelligence

Horizon Pharma plc / Crealta Holdings LLC

2015 · Acquisition/Merger · $510M · Complete

Announcement Sentiment

Neutral / mixed

Horizon Pharma agreed to acquire Crealta Holdings (backed by GTCR) for $510M cash, adding Krystexxa, the only FDA-approved biologic for chronic refractory gout, plus Migergot. Closed January 13, 2016.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Dec 11, 2015
Closed Jan 13, 2016
Deal value $510M
Deal type Acquisition/Merger
Therapeutic area Chronic refractory gout
Indications Chronic refractory gout
Key assets Krystexxa (pegloticase); Migergot
Mechanism Pegylated recombinant porcine-like uricase enzyme replacement

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals